Aldeyra stock jumps 50 percent after eye allergy trial success
Quiet local biotech Aldeyra Therapeutics made some noise Tuesday, reporting that its first treatment for eye allergies succeeded in a late-stage trial.
The 19-person company has largely flown under the radar in the Massachusetts biotech landscape, aside from raising one of the smallest amounts for a Bay State biotech IPO in 2014.
Lexington-based Aldeyra (Nasdaq: ALDX) is developing several treatments for inflammatory eye and skin conditions. Th e company announced Tuesday that its lead drug, an…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Allison DeAngelis Source Type: news
More News: Allergy | Allergy & Immunology | American Health | Biotechnology | Health Management | Skin